Products - Brain cancers | Topic | NICE

Showing 6 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
DCVax-L for treating glioblastoma [ID836]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Asunercept for treating glioblastoma [1301]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC